{"0": {"refractory cll": 0.6244632005691528, "cll": 0.5846647024154663, "cll sll": 0.5367763042449951, "clinical trials": 0.5210782885551453, "clinical trial": 0.5189774036407471, "targeted therapies": 0.5167398452758789, "combination therapies": 0.5109853744506836, "treatment paradigm": 0.5066911578178406, "treatment options": 0.5050240159034729, "ibrutinib plus": 0.5019395351409912, "previously treated": 0.49829381704330444, "plus obinutuzumab": 0.4948235750198364, "clinical": 0.49002963304519653, "treatments": 0.4869515001773834, "therapies": 0.48620373010635376, "combination therapy": 0.4772959351539612, "treatment": 0.4722215533256531, "ibrutinib": 0.4721636176109314, "efficacy": 0.4679930806159973, "targeted therapy": 0.4598436653614044, "cirmtuzumab": 0.45323675870895386, "monotherapy": 0.44493037462234497, "treatment landscape": 0.4439464807510376, "tg therapeutics": 0.4420355260372162, "chemotherapy": 0.4376826882362366, "treat": 0.43520987033843994, "pi inhibitors": 0.433750718832016, "cancer therapy": 0.4328558146953583, "refractory chronic": 0.4324271082878113, "btk inhibitors": 0.4298973083496094, "medicare": 0.42934566736221313, "treated": 0.42696118354797363, "btk inhibitor": 0.4259057641029358, "patients": 0.42503273487091064, "oncologist": 0.42416226863861084, "efficacy and safety": 0.42351746559143066, "dr abedin": 0.4225269556045532, "plus rituximab": 0.42211300134658813, "trials": 0.4176918864250183, "inhibitors": 0.41760602593421936, "therapeutics announces": 0.41541314125061035, "treating": 0.41479358077049255, "therapeutics": 0.4141697287559509, "prognostic factors": 0.4126628041267395, "patient": 0.408557653427124, "prognostic": 0.40541648864746094, "obinutuzumab combo": 0.4044773578643799, "immunotherapy": 0.40382635593414307, "inhibitor": 0.4037972688674927, "cell therapy": 0.4030609130859375}, "1": {"lymphocytic leukemia": 0.8434916734695435, "lymphocytic leukaemia": 0.7816510200500488, "leukemia": 0.7795490622520447, "leukemia hematology": 0.7747834920883179, "leukaemia": 0.7630974054336548, "chronic lymphocytic": 0.6934731602668762, "lymphocytic": 0.655756413936615, "lymphocyte": 0.6471076011657715, "lymphoma": 0.6290836930274963, "lymphocytes": 0.6239948868751526, "cancer therapy": 0.5704571008682251, "cell therapy": 0.5627715587615967, "lymphocyte count": 0.5618877410888672, "blood cancer": 0.5550143122673035, "cell malignancies": 0.5520384311676025, "blood cancers": 0.5493038892745972, "chemotherapy": 0.5489939451217651, "hematologic malignancies": 0.5484498739242554, "follicular lymphoma": 0.5474342107772827, "small lymphocytic": 0.5460265278816223, "cancers": 0.5338021516799927, "cancer": 0.5224509239196777, "bone marrow": 0.5205845832824707, "immunotherapy": 0.5129095911979675, "lymph": 0.5117496848106384, "cirmtuzumab": 0.5083143711090088, "malignancies": 0.4992715120315552, "tumor lysis": 0.48691266775131226, "swollen lymph": 0.4847143888473511, "oncology": 0.48471370339393616, "lymph nodes": 0.47724518179893494, "chemotherapy free": 0.47718799114227295, "hematologist oncologist": 0.4696432948112488, "marrow": 0.46616291999816895, "cancer survivors": 0.4558411240577698, "immune response": 0.45133113861083984, "hematology": 0.44796741008758545, "hematologic": 0.445562481880188, "cancer center": 0.44441723823547363, "plus obinutuzumab": 0.44040048122406006, "tumor": 0.4397630989551544, "cancer network": 0.4317208528518677, "oncologist": 0.42253583669662476, "cell transplant": 0.4200403690338135, "cells": 0.4192737936973572, "immune system": 0.41597795486450195, "btk inhibitors": 0.41594210267066956, "tg therapeutics": 0.4150434732437134, "monotherapy": 0.4126022458076477, "hematology advisor": 0.4117754399776459}, "2": {"car cells": 0.7085750699043274, "car cell": 0.6795434951782227, "cell therapy": 0.5448182821273804, "cancer therapy": 0.5159428119659424, "chemotherapy": 0.4953177571296692, "targeted therapies": 0.4717806875705719, "immunotherapy": 0.4641624689102173, "tg therapeutics": 0.46370381116867065, "combination therapies": 0.45841747522354126, "blood cancer": 0.44107091426849365, "efficacy and safety": 0.4387667775154114, "therapies": 0.4334005117416382, "leukemia": 0.43331533670425415, "combination therapy": 0.4314672350883484, "leukaemia": 0.42961743474006653, "blood cancers": 0.426030695438385, "leukemia hematology": 0.42321768403053284, "cell malignancies": 0.419455349445343, "immune response": 0.4186386466026306, "clinical trials": 0.4173763394355774, "treatment paradigm": 0.41658860445022583, "treatment options": 0.41597482562065125, "targeted therapy": 0.4144601821899414, "clinical trial": 0.414306640625, "cancer": 0.4113684892654419, "monotherapy": 0.40885162353515625, "chemotherapy free": 0.40811997652053833, "cancers": 0.40516766905784607, "efficacy": 0.40510988235473633, "car": 0.4040508270263672, "cd car": 0.4035647511482239, "safety and efficacy": 0.3981424868106842, "immune system": 0.3945763409137726, "lymphocytic leukemia": 0.39451658725738525, "car nk": 0.39418113231658936, "lymphocytic leukaemia": 0.3873925805091858, "treatments": 0.3840447664260864, "therapeutics": 0.38100165128707886, "therapeutics announces": 0.3798118829727173, "oncology": 0.3795464038848877, "btk inhibitors": 0.37778377532958984, "btk inhibitor": 0.37236225605010986, "chronic lymphocytic": 0.37035107612609863, "malignancies": 0.3702320456504822, "immune": 0.3655233383178711, "cells": 0.359944224357605, "oncologist": 0.35933101177215576, "therapy": 0.35893309116363525, "cell transplant": 0.3588619828224182, "trials": 0.3580532670021057}, "3": {"btk inhibitors": 0.8725008964538574, "btk inhibitor": 0.857444167137146, "btk inhibition": 0.8109474182128906, "inhibitors": 0.5212638974189758, "inhibitor": 0.5137150287628174, "tg therapeutics": 0.4811825454235077, "targeted therapies": 0.4539288282394409, "pi inhibitors": 0.44519659876823425, "cancer therapy": 0.44147998094558716, "combination therapies": 0.4273536205291748, "cell therapy": 0.42389655113220215, "targeted therapy": 0.4225805401802063, "chemotherapy": 0.42136311531066895, "treatment options": 0.41065168380737305, "combination therapy": 0.4048939049243927, "monotherapy": 0.4000949263572693, "efficacy": 0.39968955516815186, "leukaemia": 0.3994165062904358, "plus obinutuzumab": 0.39884915947914124, "leukemia": 0.3972908854484558, "treatments": 0.3934035301208496, "immune response": 0.3929964303970337, "immunotherapy": 0.39035141468048096, "inhibition": 0.39003580808639526, "leukemia hematology": 0.3850751519203186, "therapies": 0.38503968715667725, "btk": 0.38046109676361084, "treatment paradigm": 0.3791907727718353, "lymphocytic leukemia": 0.372222900390625, "antibody": 0.37021103501319885, "therapeutics": 0.3698655962944031, "treatment": 0.36804527044296265, "immune": 0.3667019009590149, "cll": 0.3657107949256897, "lymphocytic leukaemia": 0.36295002698898315, "clinical trials": 0.362039178609848, "chemo": 0.3601210415363312, "obinutuzumab combo": 0.3596218526363373, "clinical trial": 0.35296982526779175, "drug": 0.3513906002044678, "antibodies": 0.350972980260849, "chronic lymphocytic": 0.3507024943828583, "efficacy and safety": 0.3506539463996887, "immune system": 0.3478151559829712, "therapeutic": 0.34693533182144165, "anti cd": 0.3463825583457947, "lymphocytic": 0.34008780121803284, "treat": 0.3390013575553894, "oncology": 0.33707061409950256, "oncologist": 0.3358336389064789}, "4": {"covid vaccine": 0.7866989374160767, "vaccine": 0.6725778579711914, "vaccines": 0.6691040992736816, "vaccination": 0.663898766040802, "vaccinated": 0.645283579826355, "immunotherapy": 0.6420342922210693, "immune response": 0.6049098968505859, "fully vaccinated": 0.6027992367744446, "immune": 0.5625181198120117, "immune system": 0.5582857728004456, "antibody": 0.5434672832489014, "antibodies": 0.542349100112915, "blood cancer": 0.4732764661312103, "blood cancers": 0.4465573728084564, "chronic lymphocytic": 0.4273378252983093, "cell therapy": 0.42454028129577637, "leukaemia": 0.4094795286655426, "lymphocytic leukaemia": 0.4081224203109741, "cancer therapy": 0.4023301899433136, "targeted therapies": 0.3982086181640625, "hematologic malignancies": 0.39811816811561584, "prognostic": 0.3963741362094879, "prognostic factors": 0.3918793201446533, "lymphocytic": 0.3861485719680786, "infection": 0.382965624332428, "hematologic": 0.3780093789100647, "cell malignancies": 0.3769562244415283, "targeted therapy": 0.3763093650341034, "chemotherapy": 0.37604767084121704, "leukemia hematology": 0.3754231333732605, "blood": 0.37008389830589294, "monotherapy": 0.3682781457901001, "leukemia": 0.3680213689804077, "hematologist oncologist": 0.36506253480911255, "malignancies": 0.36367982625961304, "hematology": 0.36283478140830994, "lymphocyte": 0.36134588718414307, "marrow": 0.35434162616729736, "lymphocytic leukemia": 0.3515278100967407, "disease progression": 0.34990227222442627, "lymphocytes": 0.3495226502418518, "patients with chronic": 0.34481000900268555, "efficacy and safety": 0.344555526971817, "lymphoma": 0.34363439679145813, "blood work": 0.34294843673706055, "patients": 0.34220635890960693, "clinical trials": 0.3405432105064392, "cancer": 0.34019458293914795, "lymphocyte count": 0.3398629426956177, "hematology advisor": 0.33976760506629944}}